Immuno-Oncology | Specialty

Immunotherapy in Lung Cancer

June 25th 2019

SCLC: Clinical Trials of Interest Using Novel Approaches

June 25th 2019

IMpower133 in SCLC

June 25th 2019

Treating Progressive Cases of Metastatic NSCLC

June 25th 2019

TMB and Immunotherapy in Advanced NSCLC

June 25th 2019

Maintenance Therapy for Advanced Nonsquamous NSCLC

June 25th 2019

Pemetrexed for Advanced NSCLC

June 25th 2019

Antiangiogenic Therapy in Advanced NSCLC

June 25th 2019

The KEYNOTE-407 Trial in Metastatic Squamous NSCLC

June 25th 2019

Approaching Non-Driver Stage IV NSCLC

June 25th 2019

Immunotherapy in Early Stage NSCLC

June 25th 2019

Immunotherapy in Stage III NSCLC

June 25th 2019

Reactions to the PACIFIC Trial in Stage III NSCLC

June 25th 2019

Locally Advanced NSCLC and Treatment Decisions

June 25th 2019

Locally Advanced NSCLC: Staging and Diagnosis

June 25th 2019

Dr. McGregor on the Combination of Atezolizumab and Bevacizumab in RCC

June 22nd 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in renal cell carcinoma (RCC).

Does Immuno-Oncology Therapy Have a Larger Role in the Urology Clinic?

June 21st 2019

The FDA approved indications in urologic cancers for 6 immune checkpoint inhibitors since 2015. That is unquestionably a good thing for patients, but the rise of these agents means that the role of the urologist in cancer care is changing, and some urologists are still on the fence about these agents.

Dr. Bochner on Future Treatment Strategies in Early-Stage NMIBC

June 12th 2019

Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center, discusses future treatment strategies in early-stage non–muscle invasive bladder cancer.

Dr. Sonpavde on the Potential for Neoadjuvant Immunotherapy in Bladder Cancer

June 7th 2019

Guru P. Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the potential for neoadjuvant immunotherapy in bladder cancer.

Dr. McDermott on the Promise of Pembrolizumab in Non-Clear Cell RCC

June 6th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.